{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-025326","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.053917+00:00","generated_at":"2026-05-24T12:04:16.618557+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Liquidia targets final YUTREPIA approval May 23, 2025; FY 2024 net loss $130.4M","bullets":["FY 2024 revenue $14.0M (down from $17.5M) driven by Treprostinil Injection promotion; net loss $130.4M ($1.66/share) vs $78.5M loss prior year.","FDA tentative approval of YUTREPIA (PAH/PH-ILD) granted Aug 2024; final approval expected after NCI exclusivity expires May 23, 2025.","HCRx financing amended for up to $100M: $25M received at closing, $50M contingent on first YUTREPIA sale, $25M upon $100M net sales milestone.","Cash and equivalents $176.5M at Dec 31, 2024, up from $83.7M a year earlier.","ASCENT study (YUTREPIA in PH-ILD) nearing enrollment completion; L606 (liposomal treprostinil) U.S. open-label study ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-025326","json":"https://secwatch.observer/filing/0001104659-25-025326.json","markdown":"https://secwatch.observer/filing/0001104659-25-025326.md","text":"https://secwatch.observer/filing/0001104659-25-025326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465925025326/0001104659-25-025326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465925025326/tm259683d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T12:04:16.618557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}